celecoxib has been researched along with Stroke in 24 studies
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the long-term risk of gastroduodenal ulcer and cardiovascular events induced by celecoxib in a population-based, randomized, double-blind, placebo-controlled study." | 9.13 | Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention. ( Feng, GS; Lam, SK; Li, J; Li, JY; Liu, WD; Ma, JL; Pan, KF; Shen, L; Wong, BC; Xia, HH; You, WC; Zhang, L; Zhang, XD, 2008) |
| "To evaluate the effectiveness and adverse effects of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) for the primary or secondary prevention of dementia." | 9.05 | Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia. ( Devane, D; Jordan, F; Kelly, JP; McGuinness, B; Murphy, K; Passmore, P; Quinn, TJ; Tudur Smith, C, 2020) |
| "To assess the benefits and harms of celecoxib in people with rheumatoid arthritis." | 8.95 | Celecoxib for rheumatoid arthritis. ( Fidahic, M; Jelicic Kadic, A; Puljak, L; Radic, M, 2017) |
| "Patients aged 60 years and over with osteoarthritis or rheumatoid arthritis, free from established CV disease and taking chronic prescribed nsNSAIDs, were randomized to switch to celecoxib or to continue their previous nsNSAID." | 5.24 | Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT). ( Connolly, E; Findlay, E; Ford, I; Greenlaw, N; Grobbee, DE; Hallas, J; Hawkey, CJ; Hobbs, FDR; MacDonald, TM; Mackenzie, IS; McMurray, JJV; Perez-Gutthann, S; Ralston, SH; Reid, DM; Ritchie, LD; Ruschitzka, F; Scheiman, JM; Walters, MR; Webster, J; Wei, L; Wilson, A, 2017) |
| "To evaluate the long-term risk of gastroduodenal ulcer and cardiovascular events induced by celecoxib in a population-based, randomized, double-blind, placebo-controlled study." | 5.13 | Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention. ( Feng, GS; Lam, SK; Li, J; Li, JY; Liu, WD; Ma, JL; Pan, KF; Shen, L; Wong, BC; Xia, HH; You, WC; Zhang, L; Zhang, XD, 2008) |
| "To evaluate the effectiveness and adverse effects of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) for the primary or secondary prevention of dementia." | 5.05 | Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia. ( Devane, D; Jordan, F; Kelly, JP; McGuinness, B; Murphy, K; Passmore, P; Quinn, TJ; Tudur Smith, C, 2020) |
| "To assess the benefits and harms of celecoxib in people with rheumatoid arthritis." | 4.95 | Celecoxib for rheumatoid arthritis. ( Fidahic, M; Jelicic Kadic, A; Puljak, L; Radic, M, 2017) |
| "Overall, the use of NSAIDs is not associated with an increased risk of hemorrhagic stroke, although this risk was modestly significantly elevated in diclofenac and meloxicam users." | 4.93 | Nonaspirin Nonsteroidal Anti-Inflammatory Drugs and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Observational Studies. ( Matteson, EL; Thongprayoon, C; Ungprasert, P, 2016) |
| "This was a post hoc analysis from the INternational VErapamil Trandolapril STudy (INVEST), which enrolled patients with hypertension and coronary artery disease." | 3.77 | Harmful effects of NSAIDs among patients with hypertension and coronary artery disease. ( Bavry, AA; Cooper-Dehoff, RM; Gong, Y; Handberg, EM; Khaliq, A; Pepine, CJ, 2011) |
| " Naproxen users had the lowest adjusted rates of serious coronary heart disease (myocardial infarction, coronary heart disease death) and serious cardiovascular disease (myocardial infarction, stroke)/death from any cause, with respective incidence rate ratios (relative to NSAID nonusers) of 0." | 3.75 | Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. ( Arbogast, PG; Castellsague, J; Chung, CP; Daugherty, JR; García-Rodríguez, LA; Murray, KT; Ray, WA; Stein, CM; Varas-Lorenzo, C, 2009) |
| "To estimate the net cardiovascular (CV) (coronary heart disease, stroke, congestive heart failure), and gastrointestinal (GI) (peptic ulcer complications) risk-benefit public health impact of the use of celecoxib compared to non-selective NSAIDs in the arthritis population." | 3.74 | Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level. ( Castellsague, J; Maguire, A; Perez-Gutthann, S; Varas-Lorenzo, C, 2007) |
| "Using national data (2001-2003), this study explored the risk of acute myocardial infarction (AMI), angina, stroke and transient ischaemic attack (TIA) in long-term users of rofecoxib and celecoxib in Taiwan and compared this data with that for those using meloxicam." | 3.73 | Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: an observational study. ( Hsiao, FY; Huang, WF; Shih, YT; Tsai, YW; Wen, YW, 2006) |
| " Celecoxib is metabolised primarily by the cytochrome P450 (CYP) 2C9 isoenzyme and has an elimination half-life of about 11 hours in healthy individuals." | 2.41 | Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. ( Davies, NM; Day, RO; McLachlan, AJ; Williams, KM, 2000) |
| "Celecoxib treatment improved the neurologic deficit, reduced the infarct volume by 50% after 48 hours of reperfusion, and resulted in a reduced percentage of SNL areas and microglia and astroglia reactivity after 48 hours of reperfusion." | 1.48 | Celecoxib Treatment Improves Neurologic Deficit and Reduces Selective Neuronal Loss and Glial Response in Rats after Transient Middle Cerebral Artery Occlusion. ( Anuncibay-Soto, B; Fernández-López, A; Font-Belmonte, E; Pérez-García, CC; Pérez-Rodríguez, D; Santos-Galdiano, M; Ugidos, IF, 2018) |
| "Celecoxib and naproxen were not associated with increased risks." | 1.35 | Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis. ( Blum, D; Cunnington, M; Funk, MJ; Mander, A; Qizilbash, N; Webb, D; Weil, J, 2008) |
| "Among 7." | 1.33 | Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: what are the benefits of avoiding blood pressure destabilization? ( Coupal, L; Grover, SA; Zowall, H, 2005) |
| " The drug's effect as well as adverse effects should be actively sought, and dosage alterations made in order to enhance the drug's effect." | 1.32 | Introduction to monitoring. What is what you prescribed actually doing? ( George, A; Shakib, S, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (58.33) | 29.6817 |
| 2010's | 7 (29.17) | 24.3611 |
| 2020's | 3 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, H | 1 |
| Cui, E | 1 |
| Li, J | 2 |
| Ma, X | 1 |
| Jiang, X | 1 |
| Du, S | 1 |
| Qian, S | 1 |
| Du, L | 1 |
| Jordan, F | 1 |
| Quinn, TJ | 1 |
| McGuinness, B | 1 |
| Passmore, P | 1 |
| Kelly, JP | 1 |
| Tudur Smith, C | 1 |
| Murphy, K | 1 |
| Devane, D | 1 |
| Tso, MK | 1 |
| Turgeon, P | 1 |
| Bosche, B | 1 |
| Lee, CK | 1 |
| Nie, T | 1 |
| D'Abbondanza, J | 1 |
| Ai, J | 1 |
| Marsden, PA | 1 |
| Macdonald, RL | 1 |
| Fidahic, M | 1 |
| Jelicic Kadic, A | 1 |
| Radic, M | 1 |
| Puljak, L | 1 |
| Chen, YR | 1 |
| Hsieh, FI | 1 |
| Chang, CC | 1 |
| Chi, NF | 1 |
| Wu, HC | 1 |
| Chiou, HY | 1 |
| Santos-Galdiano, M | 1 |
| Pérez-Rodríguez, D | 1 |
| Anuncibay-Soto, B | 1 |
| Font-Belmonte, E | 1 |
| Ugidos, IF | 1 |
| Pérez-García, CC | 1 |
| Fernández-López, A | 1 |
| Ungprasert, P | 1 |
| Matteson, EL | 1 |
| Thongprayoon, C | 1 |
| MacDonald, TM | 1 |
| Hawkey, CJ | 1 |
| Ford, I | 1 |
| McMurray, JJV | 1 |
| Scheiman, JM | 1 |
| Hallas, J | 1 |
| Findlay, E | 1 |
| Grobbee, DE | 1 |
| Hobbs, FDR | 1 |
| Ralston, SH | 1 |
| Reid, DM | 1 |
| Walters, MR | 1 |
| Webster, J | 1 |
| Ruschitzka, F | 1 |
| Ritchie, LD | 1 |
| Perez-Gutthann, S | 2 |
| Connolly, E | 1 |
| Greenlaw, N | 1 |
| Wilson, A | 1 |
| Wei, L | 1 |
| Mackenzie, IS | 1 |
| Feng, GS | 1 |
| Ma, JL | 1 |
| Wong, BC | 1 |
| Zhang, L | 1 |
| Liu, WD | 1 |
| Pan, KF | 1 |
| Shen, L | 1 |
| Zhang, XD | 1 |
| Xia, HH | 1 |
| Li, JY | 1 |
| Lam, SK | 1 |
| You, WC | 1 |
| Ray, WA | 1 |
| Varas-Lorenzo, C | 2 |
| Chung, CP | 1 |
| Castellsague, J | 2 |
| Murray, KT | 1 |
| Stein, CM | 1 |
| Daugherty, JR | 1 |
| Arbogast, PG | 1 |
| García-Rodríguez, LA | 1 |
| Bavry, AA | 1 |
| Khaliq, A | 1 |
| Gong, Y | 1 |
| Handberg, EM | 1 |
| Cooper-Dehoff, RM | 1 |
| Pepine, CJ | 1 |
| Bäck, M | 1 |
| Yin, L | 1 |
| Ingelsson, E | 1 |
| Shakib, S | 1 |
| George, A | 1 |
| Grover, SA | 1 |
| Coupal, L | 1 |
| Zowall, H | 1 |
| Couzin, J | 2 |
| Huang, WF | 1 |
| Hsiao, FY | 1 |
| Tsai, YW | 1 |
| Wen, YW | 1 |
| Shih, YT | 1 |
| Nelson, NJ | 1 |
| Maguire, A | 1 |
| Andersohn, F | 1 |
| Suissa, S | 1 |
| Garbe, E | 1 |
| Madan, RA | 1 |
| Xia, Q | 1 |
| Chang, VT | 1 |
| Oriscello, RG | 1 |
| Kasimis, B | 1 |
| Cunnington, M | 1 |
| Webb, D | 1 |
| Qizilbash, N | 1 |
| Blum, D | 1 |
| Mander, A | 1 |
| Funk, MJ | 1 |
| Weil, J | 1 |
| Davies, NM | 1 |
| McLachlan, AJ | 1 |
| Day, RO | 1 |
| Williams, KM | 1 |
| Schnitzer, TJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 4 Study A Large Streamline Safety Study Designed to Compare the Cardiovascular Safety od Celecoxib Versus Traditional Non-selective NSAID's[NCT00447759] | Phase 4 | 7,297 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| A Phase IIa Randomized, Active-controlled, Double-blind, Dose-escalation Study in Patients With Vulvovaginal Candidiasis to Evaluate Dose Response Relationship of Clinical Efficacy, Safety and Tolerability of Topically Administered ProF-001[NCT03115073] | Phase 2/Phase 3 | 84 participants (Actual) | Interventional | 2017-04-04 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for celecoxib and Stroke
| Article | Year |
|---|---|
Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Age | 2020 |
Celecoxib for rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Humans; Myocardial Infarc | 2017 |
Nonaspirin Nonsteroidal Anti-Inflammatory Drugs and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Observational Studies.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cerebral Hemorrhage; Diclofenac; Humans; Ibuprof | 2016 |
Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Biotransform | 2000 |
2 trials available for celecoxib and Stroke
| Article | Year |
|---|---|
Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT).
Topics: Acute Coronary Syndrome; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celec | 2017 |
Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention.
Topics: Adult; Cardiovascular Diseases; Celecoxib; China; Cyclooxygenase 2 Inhibitors; Dose-Response Relatio | 2008 |
18 other studies available for celecoxib and Stroke
| Article | Year |
|---|---|
Design and synthesis of novel indole and indazole-piperazine pyrimidine derivatives with anti-inflammatory and neuroprotective activities for ischemic stroke treatment.
Topics: Animals; Anti-Inflammatory Agents; Brain Ischemia; Cyclooxygenase 2; Disease Models, Animal; Indazol | 2022 |
Gene expression profiling of brain endothelial cells after experimental subarachnoid haemorrhage.
Topics: Animals; Blood-Brain Barrier; Brain Injuries; Brain Ischemia; Celecoxib; Cyclooxygenase 2; Cyclooxyg | 2021 |
Effect on Risk of Stroke and Acute Myocardial Infarction of Nonselective Nonsteroidal Anti-Inflammatory Drugs in Patients With Rheumatoid Arthritis.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; | 2018 |
Celecoxib Treatment Improves Neurologic Deficit and Reduces Selective Neuronal Loss and Glial Response in Rats after Transient Middle Cerebral Artery Occlusion.
Topics: Animals; Astrocytes; Celecoxib; Disease Models, Animal; Infarction, Middle Cerebral Artery; Male; Ne | 2018 |
Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cohort Studies; C | 2009 |
Harmful effects of NSAIDs among patients with hypertension and coronary artery disease.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; Celec | 2011 |
Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib.
Topics: Atrial Fibrillation; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Epidemiologic | 2012 |
Introduction to monitoring. What is what you prescribed actually doing?
Topics: Acetaminophen; Aged; Aspirin; Australia; Celecoxib; Drug Interactions; Drug Therapy, Combination; Fa | 2003 |
Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: what are the benefits of avoiding blood pressure destabilization?
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; Celecoxib; C | 2005 |
Clinical trials. Halt of Celebrex study threatens drug's future, other trials.
Topics: Alzheimer Disease; Celecoxib; Clinical Trials as Topic; Colonic Polyps; Cyclooxygenase Inhibitors; D | 2004 |
Drug safety. FDA panel urges caution on many anti-inflammatory drugs.
Topics: Advisory Committees; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cy | 2005 |
Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: an observational study.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angina Pectoris; Cardiovascular Diseases; Celecoxib; | 2006 |
Celecoxib shown effective in preventing colon polyps.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Cardiovascular Diseases; Celecoxib | 2006 |
Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular D | 2007 |
Risks and benefits of celecoxib to prevent colorectal adenomas.
Topics: Adenoma; Cardiovascular Diseases; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Huma | 2006 |
A retrospective analysis of cardiovascular morbidity in metastatic hormone-refractory prostate cancer patients on high doses of the selective COX-2 inhibitor celecoxib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Case-Control Studie | 2007 |
Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Coh | 2008 |
Is concern about cardiovascular events with the new coxib class of drugs justified?
Topics: Celecoxib; Cyclooxygenase Inhibitors; Data Interpretation, Statistical; Drug Evaluation; Humans; Lac | 2001 |